(Q43047076)

12 November 2017

title

Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo (English)

1 reference

12 November 2017

1 reference

1 reference

1

1 reference

12 November 2017

2

1 reference

12 November 2017

Herold J Metselaar

3

1 reference

12 November 2017

Jaap Kwekkeboom

4

1 reference

12 November 2017

Jeroen de Jonge

5

1 reference

12 November 2017

Hugo W Tilanus

6

1 reference

12 November 2017

Harry L A Janssen

7

1 reference

12 November 2017

Luc J W van der Laan

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

18 April 2012

1 reference

12 November 2017

1 reference

12 November 2017

volume

55

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

1673-1683

1 reference

Mycophenolate mofetil and its mechanisms of action

12 November 2017

cites work

1 reference

7 January 2021

Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells

1 reference

7 January 2021

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

1 reference

7 January 2021

Identification of active antiviral compounds against a New York isolate of West Nile virus

1 reference

7 January 2021

The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase

1 reference

7 January 2021

Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells

1 reference

7 January 2021

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

1 reference

7 January 2021

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system

1 reference

7 January 2021

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

1 reference

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

7 January 2021

Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element.

1 reference

7 January 2021

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

1 reference

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

7 January 2021

Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis

1 reference

7 January 2021

Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety

1 reference

7 January 2021

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

1 reference

7 January 2021

Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication

1 reference

7 January 2021

The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus

1 reference

7 January 2021

A diverse range of gene products are effectors of the type I interferon antiviral response

1 reference

7 January 2021

High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma

1 reference

7 January 2021

Metabolic fate of ethyl O-[N-(p-carboxyphenyl)-carbamoyl] mycophenolate (CAM), a new antitumor agent, in experimental animals

1 reference

7 January 2021

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

1 reference

7 January 2021

Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells

1 reference

7 January 2021

Hepatitis C and mycophenolate mofetil--a clarification

1 reference

7 January 2021

Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation

1 reference

7 January 2021

MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course

1 reference

7 January 2021

Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation

1 reference

7 January 2021

Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil

1 reference

7 January 2021

A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

1 reference

7 January 2021

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

1 reference

7 January 2021

Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C

1 reference

7 January 2021

Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection

1 reference

7 January 2021

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

1 reference

7 January 2021

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

1 reference

7 January 2021

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.25562

1 reference

12 November 2017

1 reference